课题基金 / 基金详情

PROTOCOL REVIEW AND MONITORING SYSTEM (Core-010)

PROTOCOL REVIEW AND MONITORING SYSTEM (Core-010)
方案审查和监测系统(Core-010)
批准号:
10260737
负责人:
Carlos L Arteaga
金额:
$8.01万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-03 至 2021-07-31

项目摘要

项目成果

Carlos L Arteaga的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Harold C. Simmons Cancer Center Protocol Review and Monitoring System (PRMS) Project Summary/Abstract The goal of the Protocol Review and Monitoring System (PRMS) is to ensure the highest scientific quality of clinical oncology research at UTSW and consists of three Cancer Center Protocol Review and Monitoring Committees (PRMCs), the Data and Safety Monitoring Committee (DSMC), and the administrative support services of the Clinical Research Office. These entities are overseen by the Clinical Cancer Research Committee, which reports to the Cancer Center's Deputy Director. The SCC has three PRMCs; two “general” committees, each of which meets monthly, and one reserved for Population Studies. PRMC1 and PRMC2 have the same responsibilities, but were created with staggered meeting dates so as to allow more timely review and approval of new protocols. The Population Sciences PRMC is responsible for protocols related to Population Sciences and Cancer Control. The three PRMCs review and monitor all cancer-related clinical studies for scientific merit prior to IRB review. The PRMCs have the authority to open protocols that meet the scientific merit and scientific priorities of the SCC, and to close protocols that do not demonstrate scientific progress. The focus of the PRMCs is on scientific merit, study prioritization, and progress of Cancer Center clinical trials. Studies which have already undergone rigorous peer review at the national level, such as NCI-approved national cooperative group studies are reviewed administratively by the PRMC Chair.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Role of HER2 mutations in breast cancer progression and response to targeted therapies
  • 批准号:
    9759820
  • 项目类别:
  • 资助金额:
    $35.74万
  • 财政年份:
    2018
  • 负责人:
    Carlos L Arteaga
  • 依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
  • 批准号:
    10214565
  • 项目类别:
  • 资助金额:
    $36.83万
  • 财政年份:
    2018
  • 负责人:
    Carlos L Arteaga
  • 依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
  • 批准号:
    10458531
  • 项目类别:
  • 资助金额:
    $36.09万
  • 财政年份:
    2018
  • 负责人:
    Carlos L Arteaga
  • 依托单位:
海外基金